CD4 and ovarian cancer: In the present study, the CD3+, CD4+, and CD3+/CD4+ levels of patients in the experimental group were higher than those in the observation group after treatment, indicating that CRS plus HIPEC could better enhance the immune function of ovarian cancer patients.